The FDA has granted a Fast Track designation to Cadrenal Therapeutics Inc's (NASDAQ:CVKD) tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib). Fast Track is a process designed to facilitate the development and expediting of the review of drugs to treat serious conditions. Fast Track aims to get important new drugs to the patient earlier. The FDA had previously granted an Orphan Drug Designation (ODD) for tecarfarin. The FDA grants orphan status to drugs targeting rare diseases ...